GBA Presents: THE BARE ESSENTIALS

vanzandt said:
Get in ABT Stoney.
$116 is a decent price.
It might drop out of the gate though.
More...


I have been looking at ABT all morning Van. I like the Co. What concerns me is over $3 B in worldwide Covid testing-- that could really shrink.

I have been noticing that nearly every move I make to counter this virus is met with disdain by the market.
 
Therapeutics, Inc. (BTAI)-
Spiked to $16.20 yest on some financing... and retreated.

Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of prostate cancer and is currently in Phase 2 clinical trials

About BXCL701

BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment. Approved and experimental immunotherapies often struggle to address cancers that appear “cold” or uninflamed. Therefore, BXCL701 may render “cold” tumors “hot,” making them more detectable by the adaptive immune system and thereby facilitating the development of a strong anti-cancer immune response. BioXcel Therapeutics’ preclinical data supports BXCL701’s synergy with both current checkpoint inhibitor-based therapies and emerging immunotherapies directed to activate T-cells. BXCL701 is currently being developed as therapy for mCRPC of adenocarcinoma and SCNC phenotypes (both “cold” tumors) and other advanced solid cancers that are “hot” or have become resistant to checkpoint inhibitors. BXCL701 has received Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) in four indications.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
14.93+0.16(+1.08%)
At close: April 19 04:00PM EDT
15.00+0.07(+0.47%)<----------- YES!
Pre-Market:8:20AM EDT
 
stonedinvestor said:
I have been looking at ABT all morning Van. I like the Co. What concerns me is over $3 B in worldwide Covid testing-- that could really shrink.

I have been noticing that nearly every move I make to counter this virus is met with disdain by the market.
More...
Have you ever heard of the dividend Aristocrat Club lol?
We need to look them up Stoney. See who else is in there.

Abbott has increased its dividend payout for 50 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

http://archive.fast-edgar.com/20220420/AQB2G22C8Z22QJZZ279R2ZZZMBP872W2Z242/
 
--> Upon closing of this transaction, and together with the Company's cash balance and anticipated business plan, BioXcel Therapeutics is expected to have a substantial multi-year working capital runway. Full execution of this financing would result in cash runway into 2025 for the Company.

Folks!!! I had to read this five times....
BioXcel Therapeutics price target raised to $134 from $130 at H.C. Wainwright 06:08 BTAI H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BioXcel Therapeutics to $134 from $130 and keeps a Buy rating on the shares. The analyst says BXCL501 approval was received on time.

THIS WAS MADE THURS LAST WEEK!!!!! YES I DON'T KNOW HOW I MISSED IT-- YES A RAISED TARGET NO LESS TO $134 AND TE STK IS $15<-----------------

--> HOLY CRAP!
 
4/7

BioXcel Therapeutics price target raised to $84 from $81 04/07 BTAI Canaccord analyst Sumant Kulkarni raised the firm's price target on BioXcel Therapeutics to $84 from $81 and keeps a Buy rating on the shares. The analyst noted its Igalmi was approved with a solid label and said the focus will now shift to the product launch in Q3 noting the company has not yet provided a price. He believes the approval adds to the company's scarcity value significantly as the company now joins the relatively small group of neuro-focused companies that have an approved product with more indications coming.
 
stonedinvestor said:
I have been looking at ABT all morning Van. I like the Co. What concerns me is over $3 B in worldwide Covid testing-- that could really shrink.

I have been noticing that nearly every move I make to counter this virus is met with disdain by the market.
More...
Put in a good till cancel order for $108.
It could drop that far this week.
 
WED APRIL 27 -- AR EARNINGS<----- NEED TO BE IN BEFORE THAT I THINK.... //

Axsome Therapeutics, Inc. (AXSM) UP HUGE YEST... MAYBE BIO COMING BACK....

40.92+8.22(+25.14%)<--------
At close: April 19 04:00PM EDT
 
Top 10 S&P 500 Dividend Aristocrats Constituents by Index Weight

upload_2022-4-20_8-42-26.jpeg


Look Stoney>>> my AbbVie :sneaky:
 
<<<THE OFFICIAL GUMYBEAR ADVISORS BARE ESSENTIAL PORTFOLIO>>>

APRIL 18 prices-

DAVE & BUSTERS-$46.50

CONSTELLATION BRANDS$254

US FOOD-$36

RH-$326

LESL-$20.15

ABEV-$3.12

SHAK- $61.60

NIKE- $132

STEVE MADDON- $41

DESIGNER BRANDS- DSW- $14.80

<<GBA SPECIAL SITUATIONS>>

SIX FLAGS $41.50

XPOF-$22.50

DOUG (RE NY & Fla)-$6.75

ACC CAMPUS (Kids College And dorms) $57.50-XXXXXXXXXXXXXXXX SOLD BIG GAIN

EVOLVE tech- (security from guns public transit) $2.50

<<GBA TECH>>

--> WOLF-$115

-->UPST- $79.50

-->PLTR-$12

PFE-$52-XXXXXXXXXXXXXXXXXXX SOLD TINY LOSS

NFLX-$333-XXXXXXXXXXXXXXXXXX SOLD BIG GAIN
 
You must log in or register to reply here.
Back
Top